Folks, this is "money." It's not bragging rights or expected clinical data. Cold, hard cash, and that's going to move the stock price substantially!
Some people just don`t know how to connect the dots-Either Iplex is going to be sold or the whole company-Shire can afford it.I`m not sure The board will let Iplex go for anything less than a kings ransom,so it might be a better deal for Shire to try and buy Insmed all together.
Sentiment: Strong Buy
On May 25, 2012, the Company entered into an agreement with Premacure
Holdings AB and Premacure AB of Sweden (collectively, "Premacure")
pursuant to which the Company agreed to grant to Premacure an exclusive,
worldwide license to develop manufacture and commercialize IGF-1, with
its natural binding protein, IGFBP-3, for the prevention and treatment
of complications of preterm birth. (the " Premacure License Agreement").
Premacure is currently focusing on retinopathy of prematurity. IGF- and
IGFBP-3 were previously developed by the Company at higher
concentrations as IPLEX®. The license is subject to the Company's
receipt of a consent and waiver from Tercica, Inc., now the Ipsen Group
("Tercica") and from Genentech, Inc., now owned by Roche ("Genentech"),
of certain rights granted by the Company to Tercica and Genentech under
the Settlement, License and Development Agreement dated March 5, 2007
(the "Waivers"). The Premacure License Agreement includes diligence
milestones and royalty payments on prospective product sales.
Sentiment: Strong Buy
Very interesting that Shire be interested in such small indication of ROP. Good to have such a large partner now. Well maybe they are interested in getting all rights for IPLEX....=) That would be a huge plus for us
For a company that has basically removed iPlex from its marketing materials, including their website, you seem convinced this is big news and this will help the SP.
As a long suffering long, I am not expecting this to have ANY sustainable impact on the SP soon, if at all. I gave up on iPlex when Insmed bought Transave. As usual, pianoman, you over-hype news.
INSM's SP is dependent upon the Arikace trials, and if you believe otherwise, then maybe you still believe in Santa Claus and the Tooth Fairy.
(Reuters) - Shire increased its investment in rare diseases on Tuesday by acquiring privately held Swedish biotech firm Premacure, which is developing a drug for a potentially blinding eye disorder in premature babies.
Britain's third biggest drugmaker did not reveal how much it was paying for the Uppsala-based business but said it would pay a sum upfront followed by contingent payments based on clinical development and commercial success.
The acquisition takes Shire into the new area of neonatology - the treatment of sick or premature newborn infants - and expands its already substantial presence in rare diseases.
Treating diseases that affect only a small number of patients is a growing focus for many drug companies given the high prices that can be achieved.
Premacure, which was launched in 2006, has an experimental protein replacement medicine in mid-stage Phase II clinical development for the prevention of retinopathy of prematurity (ROP).
Normal full-term babies produce enough growth factors on their own to prevent diseases like ROP. But those born before 31 weeks may lack chemicals such as insulin-like growth factor 1 (IGF-1), which can result in life-long complications like ROP.
Shire said its human genetic therapies unit would continue with the Phase II study, the primary goal of which is to restore the IGF-1 levels in premature infants to those found in babies born at full term.